Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma.

Raquibul HannanOsama MohamadAlberto Diaz de LeonSubrata MannaLaurentiu M PopZe ZhangSamantha MannalaAlana ChristieScott ChristleyNancy MonsonDan IshiharaEric J HsuChul AhnPayal KapurMingyi ChenYull ArriagaKevin Dale Courtney Brandi L CantarelEdward K WakelandYang-Xin FuIvan PedrosaLindsay CowellTao WangVitaly MargulisHak ChoyRobert D TimmermanJames Brugarolas

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Adding SAbR did not improve the response rate to HD IL2 in patients with mRCC in this study. Tissue analyses suggest a possible correlation between frameshift mutation load as well as tumor immune infiltrates and clinical outcomes.

Keyphrases

high dose
metastatic renal cell carcinoma
early stage
low dose
radiation therapy
locally advanced
radiation induced
randomized controlled trial
small cell lung cancer
open label
squamous cell carcinoma
clinical trial
brain metastases
rectal cancer